Research

Hormonal

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) significantly reduce AHI and body weight in patients with obesity and moderate-to-severe OSA, with tirzepatide showing superior efficacy compared to other GLP-1 RAs.

If you have obesity and moderate-to-severe sleep apnea, ask your doctor about GLP-1 receptor agonists like tirzepatide (Zepbound). These medications help with weight loss and have been shown to significantly reduce the severity of sleep apnea. They are taken as a weekly injection and can have gastrointestinal side effects, but these often improve over time. This treatment is particularly beneficial for those whose OSA is driven by obesity.

GoodSupportsHIGH confidence
In studies involving OSA, tirzepatide led to substantial body weight reductions (17.7–19.6%) and pronounced decreases in AHI (−20 to −23.8 events/hour) among obese patients with moderate-to-severe OSA [133].
Soo Kyoung Park et al. · Journal of Clinical Medicine · 2025

Why this rating

Based on randomized controlled trials (SURMOUNT-OSA) and meta-analyses.

Source

Advancing Obstructive Sleep Apnea Management: Recent Trends from Conventional to Innovative Therapies

Soo Kyoung Park et al. · Journal of Clinical Medicine · 2025

DOI 10.3390/jcm14217586

narrative_reviewCited 6×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →